Abstract:Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a key regulator of plasma LDL-cholesterol (LDL-C) and a clinically validated target for the treatment of hypercholesterolemia and coronary artery disease. In this paper, we describe a series of novel cyclic peptides derived from an mRNA display screen which inhibit the protein–protein interaction between PCSK9 and LDLR. Using a structure-based drug design approach, we were able to modify our original screening lead 2 to optimize the potency and metabolic stability and minimize the molecular weight to provide novel bicyclic next-generation PCSK9 inhibitor peptides such as 78. These next-generation peptides serve as a critical foundation for continued exploration of potential oral, once-a-day PCSK9 therapeutics for the treatment of cardiovascular disease.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01084?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01084</a>.Representative LC traces for key molecules in the paper, sample IC50 curves for LDLR-FRET and Alexa-FRET assay control peptide, and raw concentration versus time profiles for molecules tested in Mouse IV PK 3D PDB files for each of the new crystal structures have also been uploaded; PDB codes for the crystal structures shown in the paper are as follows: compound 30, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XIB">6XIB</a>; compound 40, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XIC">6XIC</a>; compound 51, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XID">6XID</a>; compound 78, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XIE">6XIE</a>; and compound 84, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XIF">6XIF</a>; and authors will release the atomic coordinates and experimental data upon article publication (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_001.pdf">PDF</a>)6xib (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_002.pdb">PDB</a>)6xic (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_003.pdb">PDB</a>)6xid (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_004.pdb">PDB</a>)6xie (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_005.pdb">PDB</a>)6xif (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_006.pdb">PDB</a>)This article has not yet been cited by other publications.

Synthesis of a Complex and Highly Potent PCSK9 Inhibitor

Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design

Potential acridinedione derivatives for the development of a heterobifunctional PROTAC for targeted degradation of PCSK9 protein

Fused Bicyclic Caspase‐1 Inhibitors Assembled by Copper‐Free Strain‐Promoted Alkyne–Azide Cycloaddition (SPAAC)

In Vitro Assays for the Discovery of PCSK9 Autoprocessing Inhibitors

Structure-activity relationship and biological evaluation of xanthine derivatives as PCSK9 inhibitors for the treatment of atherosclerosis

PCSK9 inhibitors as safer therapeutics for atherosclerotic cardiovascular disease (ASCVD): Pharmacophore design and molecular dynamics analysis

Targeting Allosteric Site of PCSK9 Enzyme for the Identification of Small Molecule Inhibitors: An In Silico Drug Repurposing Study

Proprotein Convertase Subtilism/kexin Type 9 Inhibitors: a New Strategy of Regulating Cholesterol

Synthesis of Hydroxyethylene-based β-Secretase Inhibitors

Identification of 4-amino-2-Pyridones as new potent PCSK9 inhibitors: From phenotypic hit discovery to in vivo tolerability

Computational Design and Biological Evaluation of Analogs of Lupin Peptide P5 Endowed with Dual PCSK9/HMG-CoAR Inhibiting Activity

An oral antisense oligonucleotide for PCSK9 inhibition

Acyclic Triterpenoids from Alpinia katsumadai Seeds with Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Secretion Inhibitory Activity

Targeted Degradation of PCSK9 In Vivo by Autophagy-Tethering Compounds

Scalable synthesis and structural characterization of reversible KLK6 inhibitors

PCSK9 Inhibition: From Current Advances to Evolving Future

Improving Stability Enhances In Vivo Efficacy of a PCSK9 Inhibitory Peptide

Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors

Facile Entry to an Efficient and Practical Enantioselective Synthesis of A Polycyclic Cholesteryl Ester Transfer Protein Inhibitor

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside